Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Why the study?
Does sotagliflozin reduce cardiovascular death and heart failure events in patients with diabetes and recent worsening heart failure?
Population
Patients with diabetes and recent worsening heart failure
Comparison
Sotagliflozin initiated before or shortly after discharge vs placebo
Authors
Discussion
Loading...
Member takes
Implication
Supports initiation near discharge in diabetic patients with recent worsening HF; extends SGLT inhibitor benefits to the post-acute phase.
Structured PICO
Does sotagliflozin reduce cardiovascular death and heart failure events in patients with diabetes and recent worsening heart failure?
P
Population
Patients with diabetes and recent worsening heart failure
I
Intervention
Sotagliflozin therapy, initiated before or shortly after discharge
C
Comparator
Placebo
O
Outcome
Total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failurecomposite
In patients with diabetes and recent worsening heart failure, sotagliflozin initiated around the time of discharge significantly reduces cardiovascular deaths and heart failure events.
Cite This Study
Bhatt et al. (2020) studied this question.